Passage BIO, Inc.

PASG Nasdaq CIK: 0001787297

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address ONE COMMERCE SQUARE, PHILADELPHIA, PA, 19103
Mailing Address ONE COMMERCE SQUARE, PHILADELPHIA, PA, 19103
Phone 2678660312
Fiscal Year End 1231
EIN 822729751

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
10-K Annual financial report March 3, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
4 Insider stock transaction report January 12, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report January 12, 2026 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC

Annual Reports

10-K March 3, 2026
  • Passage BIO is a genetic medicines company focused on developing gene therapies for rare genetic brain and spinal cord disorders.
  • The company leverages scientific expertise and proprietary technologies to address unmet medical needs.
View Analysis

Material Events

8-K Strategy Change March 10, 2026
High Impact
  • Streamlines operations and strengthens financial position through proactive management.
  • Sharpens focus on core mission: advancing promising drug candidates for neurological diseases.
View Analysis

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.